医学部

hiratsuka izumi

  (平塚 いづみ)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
医学博士(藤田保健衛生大学)

J-GLOBAL ID
201601015097701017
researchmap Member ID
7000015579

Research Interests

 2

Research History

 1

Education

 2

Awards

 2

Papers

 10
  • Izumi Hiratsuka, Hiroya Yamada, Mitsuyasu Itoh, Megumi Shibata, Takeshi Takayanagi, Masaki Makino, Yoshihisa Sugimura, Nobuki Hayakawa, Shuji Hashimoto, Atsushi Suzuki
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 128(2) 119-124, Feb, 2020  Peer-reviewed
    OBJECTIVE: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition that can affect almost any organ. We investigated the association between IgG4-RD and the main characteristics of Graves' disease (GD) at the time of diagnosis. Additionally, we evaluated whether serum IgG4 levels change during treatment. DESIGN AND PATIENTS: Twenty-eight patients with newly diagnosed GD were enrolled into this longitudinal follow-up study. Serum IgG4 levels and thyroid function were measured in all the participants at the time of diagnosis. Further, the serum IgG4 levels of nine of 28 patients with untreated GD were measured after the achievement of euthyroid state (through the use of methimazole). RESULTS: Two (7.1%) of 28 patients with untreated GD had elevated serum IgG4 levels of >135 mg/dL. There was no significant difference in the average IgG4 levels before and after the achievement of euthyroid state (66.2±74.0 mg/dL vs. 50.5±47.3 mg/dL). In two patients, the elevated serum IgG4 levels returned to normal after treatment. However, one patient had an elevated serum IgG4 level of 136.6 mg/dL after treatment. CONCLUSIONS: This study showed that serum IgG4 levels varied with treatment in patients with GD, independent of thyroid function, suggesting that IgG4 might be indirectly related to GD.
  • Mizuho Kondo-Ando, Yusuke Seino, Risa Morikawa, Kana Negi, Hidechika Todoroki, Tsukasa Kawakami, Yohei Asada, Ryo Yoshimoto, Chika Tanaka, Keiko Okamoto, Atsushi Masuda, Eisuke Tomatsu, Izumi Hiratsuka, Yasumasa Yoshino, Wakako Maki, Ayako Kakita, Megumi Shibata, Takeshi Takayanagi, Masaki Makino, Yoshihisa Sugimura, Shiho Asai, Akemi Ito, Shinji Ueno, Yuuka Fujiwara, Hitoshi Kuwata, Daisuke Yabe, Atsushi Suzuki
    Journal of diabetes and its complications, 33(11) 107415-107415, Nov, 2019  Peer-reviewed
    AIMS: The aim of this study is to investigate the effects of a low-carbohydrate staple food (i.e., low-carbohydrate bread) on glucose and lipid metabolism and pancreatic and enteroendocrine hormone secretion in comparison with meals containing normal-carbohydrate bread, without consideration of the carbohydrate content of the side dishes. METHODS: T2DM patients (n = 41) were provided meals containing low-carbohydrate bread (LB) together with side dishes or normal-carbohydrate bread (NB) together with side dishes every other day as a breakfast. Blood glucose levels were evaluated by using a continuous glucose monitoring system; blood samples were collected before and 1 and 2 h after the breakfast. RESULTS: Postprandial blood glucose levels, plasma insulin, plasma glucose-dependent insulinotropic polypeptide (GIP) and plasma triglyceride were significantly lower and plasma glucagon levels were significantly higher in LB compared with those in NB. Plasma glucagon-like peptide-1 (GLP-1) levels did not differ in the LB and NB groups. CONCLUSIONS: These results indicate that changing only the carbohydrate content of the staple food has benefits on glucose and lipid metabolism in T2DM patients concomitant with the decrease of insulin and GIP secretion, which ameliorate body weight gain and insulin resistance.
  • Ito T, Kenmochi T, Aida N, Kurihara K, Kawai A, Suzuki A, Shibata M, Hiratsuka I, Hasegawa M
    Journal of clinical medicine, 8(9), Sep, 2019  Peer-reviewed
  • Aida N, Kenmochi T, Ito T, Nishikawa T, Hiratsuka I, Shibata M, Suzuki A, Hasegawa M, Kawai A, Kusaka M, Hoshinaga K, Matsubara H
    Pancreas, 47(5) 617-624, May, 2018  Peer-reviewed
  • Shibata M, Ihara Y, Hiratsuka I, Sekiguchi-Ueda S, Takayanagi T, Makino M, Hayakawa N, Suzuki A
    Fujita Medical Journal, 3(2) 44-47, 2017  Peer-reviewed
    <p>  A 34-year-old woman with type 1 diabetes on hemodialysis was admitted to our hospital for simultaneous pancreas kidney transplantation received from her father. She had suffered from type 1 diabetes mellitus since age 13, and had complained of serious atonic gastroenteropathy and orthostatic hypotension. After the transplantation, she became free from hemodialysis and insulin injection. At the same time, her gastrointestinal symptoms disappeared. However, she still had orthostatic hypotension, which was improved by taking fludrocortisone. Two months after the transplantation, orthostatic hypotension with marked polyuria became obvious. By hypertonic saline challenge test, she was diagnosed as partial central diabetes insipidus. Although treatment with desmopressin was necessary for 5 months, she became free from medication afterwards. Diabetes insipidus seems to be a rare but could be an important complication after simultaneous pancreas kidney transplantation and/or or kidney transplantation.</p>

Books and Other Publications

 3